TTrialPathMatch Me to Trials
← Back to trials
RecruitingEndometrial Cancer

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Eligible age

18+ yrs

Accepts

Women

Locations

11 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

Sponsor: Faeth Therapeutics

You may qualify if…

  • ✓ Histologically confirmed diagnosis of endometrioid endometrial carcinoma.
  • ✓ Documented evidence of advanced or recurrent endometrial cancer that is not amenable to surgery/radiation for curative intent.
  • ✓ Participant has received at least 1 but not more than 4 prior systemic therapies. Prior therapy must include platinum-based chemotherapy and a checkpoint inhibitor, either separately or in combination. If a subject has been unable to be treated with checkpoint inhibitor in the past due to medical contraindications, consult with Medical Monitor.
  • ✓ PI3K/AKT/mTOR pathway gene alteration identified.
  • ✓ At least 1 measurable target lesion according to RECIST v1.1
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at Screening.
  • ✓ Non-pregnant, non-lactating females who are postmenopausal, surgically sterile or who agree to use effective contraceptive methods..

You may not qualify if…

  • ✕ Participants with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study
  • ✕ Active malignancy (except for endometrial cancer, definitively treated in-situ carcinomas \[e.g., breast, cervix, bladder\], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible.
  • ✕ Gastric feeding tube (gastrostomy tube), gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment.
  • ✕ Clinically significant (per Investigator judgement) hemoptysis or tumor bleeding.
  • ✕ Significant cardiovascular impairment.
  • ✕ Active, uncontrolled (requiring systemic antimicrobial therapy) infection.
  • ✕ Concurrent participation in another therapeutic clinical trial.
  • ✕ Prior radiation therapy within 21 days prior to start of study treatment.

Where it's recruiting

California

La Jolla · San Francisco

Florida

Miami Beach · St. Petersburg · West Palm Beach

Maryland

Brandywine

Minnesota

Maple Grove

New York

Albany · New York

Ohio

Cincinnati

Oregon

Eugene · Portland

Pennsylvania

Doylestown · Pittsburgh

South Dakota

Sioux Falls

Texas

El Paso · The Woodlands

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT06463028 · last updated 2025-12-24